Literature DB >> 16867867

Expression of cadherins and catenins correlates with distinct histologic types of ovarian carcinomas.

David Sarrió1, Gema Moreno-Bueno, Carolina Sánchez-Estévez, Inmaculada Bañón-Rodríguez, Ginés Hernández-Cortés, David Hardisson, José Palacios.   

Abstract

Alterations in the cadherin-catenin expression and activation of the Wnt signaling have been related to the pathology of ovarian carcinomas. Here, we evaluated the immunoreactivity of cadherins (E-, P-, and N-cadherin and cadherin-11) and catenins (alpha-, beta-, and gamma-catenin and p120) in 86 ovarian tumors. We found significant differences in the expression of all cadherins and catenins among the distinct histologic tumor types. Clear cell tumors were rarely N-cadherin- and P-cadherin-positive and showed reduced membranous expression in all the catenins; Serous carcinomas were frequently N-cadherin- and P-cadherin-positive, mucinous tumors strongly expressed E-cadherin and the catenins in the membrane, and endometrioid tumors characteristically expressed nucleocytoplasmic beta-catenin in most of the cases. We next studied whether allelic losses in the chromosomal regions containing various cadherin genes (16q22) or APC gene (5q21) occurred in ovarian tumors and observed a high frequency of loss of heterozygosity in 16q22 (78%) and 5q21 (33%) regions, but there were no differences among the tumor types analyzed. Finally, we also assessed the molecular alterations responsible for beta-catenin nuclear accumulation in endometrioid tumors by screening for mutations in AXIN1, AXIN2, APC, and KRAS genes. Mutations in KRAS were observed in 2 of 19 tumors, but no mutations were detected in AXIN1, AXIN2, or APC genes. Only beta-catenin gene mutations were associated with nuclear beta-catenin staining in these tumors. In conclusion, different cadherin-catenin expression patterns are associated with distinct histologic types. Oncogenic Wnt signaling plays a role only in endometrioid tumors, where beta-catenin mutations seem to be the main cause of its aberrant expression.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16867867     DOI: 10.1016/j.humpath.2006.03.003

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  26 in total

Review 1.  Unmasking the complexities of mucinous ovarian carcinoma.

Authors:  Michael Frumovitz; Kathleen M Schmeler; Anais Malpica; Anil K Sood; David M Gershenson
Journal:  Gynecol Oncol       Date:  2010-03-23       Impact factor: 5.482

2.  Targeting SRC in mucinous ovarian carcinoma.

Authors:  Koji Matsuo; Masato Nishimura; Justin N Bottsford-Miller; Jie Huang; Kakajan Komurov; Guillermo N Armaiz-Pena; Mian M K Shahzad; Rebecca L Stone; Ju Won Roh; Angela M Sanguino; Chunhua Lu; Dwight D Im; Neil B Rosenshien; Atsuko Sakakibara; Tadayoshi Nagano; Masato Yamasaki; Takayuki Enomoto; Tadashi Kimura; Prahlad T Ram; Kathleen M Schmeler; Gary E Gallick; Kwong K Wong; Michael Frumovitz; Anil K Sood
Journal:  Clin Cancer Res       Date:  2011-07-07       Impact factor: 12.531

3.  Wnt and hedgehog gene pathway expression in serous ovarian cancer.

Authors:  Seraina Schmid; Marcia Bieber; Fang Zhang; Mallory Zhang; Biao He; David Jablons; Nelson N H Teng
Journal:  Int J Gynecol Cancer       Date:  2011-08       Impact factor: 3.437

4.  WNT7A regulates tumor growth and progression in ovarian cancer through the WNT/β-catenin pathway.

Authors:  Shin Yoshioka; Mandy L King; Sophia Ran; Hiroshi Okuda; James A MacLean; Mary E McAsey; Norihiro Sugino; Laurent Brard; Kounosuke Watabe; Kanako Hayashi
Journal:  Mol Cancer Res       Date:  2012-01-09       Impact factor: 5.852

Review 5.  Helicobacter pylori and gastric cancer: factors that modulate disease risk.

Authors:  Lydia E Wroblewski; Richard M Peek; Keith T Wilson
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

Review 6.  Mucinous tumors of the ovary: current thoughts on diagnosis and management.

Authors:  Jubilee Brown; Michael Frumovitz
Journal:  Curr Oncol Rep       Date:  2014-06       Impact factor: 5.075

7.  Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth.

Authors:  Murali M Yallapu; Diane M Maher; Vasudha Sundram; Maria C Bell; Meena Jaggi; Subhash C Chauhan
Journal:  J Ovarian Res       Date:  2010-04-29       Impact factor: 4.234

Review 8.  Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management.

Authors:  Henry T Lynch; Murray Joseph Casey; Carrie L Snyder; Chhanda Bewtra; Jane F Lynch; Matthew Butts; Andrew K Godwin
Journal:  Mol Oncol       Date:  2009-02-21       Impact factor: 6.603

9.  Autoantibody profiling to identify biomarkers of key pathogenic pathways in mucinous ovarian cancer.

Authors:  Liangdan Tang; Junzheng Yang; Shu-Kay Ng; Noah Rodriguez; Pui-Wah Choi; Allison Vitonis; Kui Wang; Geoffrey J McLachlan; Robert J Caiazzo; Brian C-S Liu; William R Welch; Daniel W Cramer; Ross S Berkowitz; Shu-Wing Ng
Journal:  Eur J Cancer       Date:  2010-01       Impact factor: 9.162

10.  Reduced expression of E-cadherin/catenin complex in hepatocellular carcinomas.

Authors:  Bo Zhai; He-Xin Yan; Shu-Qin Liu; Lei Chen; Meng-Chao Wu; Hong-Yang Wang
Journal:  World J Gastroenterol       Date:  2008-10-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.